BONESUPPORT reported 1Q24 orthopedic sales of SEKm 184.4 (USD $17.2 million), up 54% compared to the first quarter of 2023.
New customer acquisition and deeper account penetration for CERAMENT G drove 65% North American sales growth. In Europe and the rest of the world, BONESUPPORT’s direct markets in Europe accounted for 85% of sales outside the U.S.
CERAMENT G received FDA approval for use in open fractures, and CERAMENT BVF also received FDA clearance in late March for use in interbody fusion procedures. The rapid approvals and broad indications solidify CERAMENT’s place as an orthobiologics platform technology.
The company estimates that 140,000 bone graft surgeries are performed on open fractures annually in the U.S., with approximately 40% of those using antibiotics. CERAMENT G is the only resorbable, FDA-approved synthetic bone graft with antibiotic elution.
BONESUPPORT expects 2024 sales of approximately $80 million, reflecting 40% growth.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment
1Q24
1Q23
$ Chg
% Chg
Orthobiologics
$17.2
$11.1
$6.0
54%
Orthopedic Sales by Geography
Region
1Q24
1Q23
$ Chg
% Chg
North America
$13.2
$8.0
$5.2
64.6%
EU and ROW
$4.0
$3.1
$0.9
27.1%
Total
$17.2
$11.1
$6.0
54%
BONESUPPORT reported 1Q24 orthopedic sales of SEKm 184.4 (USD $17.2 million), up 54% compared to the first quarter of 2023.
New customer acquisition and deeper account penetration for CERAMENT G drove 65% North American sales growth. In Europe and the rest of the world, BONESUPPORT’s direct markets in Europe accounted for 85% of sales...
BONESUPPORT reported 1Q24 orthopedic sales of SEKm 184.4 (USD $17.2 million), up 54% compared to the first quarter of 2023.
New customer acquisition and deeper account penetration for CERAMENT G drove 65% North American sales growth. In Europe and the rest of the world, BONESUPPORT’s direct markets in Europe accounted for 85% of sales outside the U.S.
CERAMENT G received FDA approval for use in open fractures, and CERAMENT BVF also received FDA clearance in late March for use in interbody fusion procedures. The rapid approvals and broad indications solidify CERAMENT’s place as an orthobiologics platform technology.
The company estimates that 140,000 bone graft surgeries are performed on open fractures annually in the U.S., with approximately 40% of those using antibiotics. CERAMENT G is the only resorbable, FDA-approved synthetic bone graft with antibiotic elution.
BONESUPPORT expects 2024 sales of approximately $80 million, reflecting 40% growth.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment
1Q24
1Q23
$ Chg
% Chg
Orthobiologics
$17.2
$11.1
$6.0
54%
Orthopedic Sales by Geography
Region
1Q24
1Q23
$ Chg
% Chg
North America
$13.2
$8.0
$5.2
64.6%
EU and ROW
$4.0
$3.1
$0.9
27.1%
Total
$17.2
$11.1
$6.0
54%
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
